N4 Pharma (GB:N4P) has released an update.
N4 Pharma PLC has announced promising results from its latest oral delivery research for Nuvec®, a cutting-edge system designed for cancer treatments and vaccines. The study, in collaboration with the University of Queensland, showed that Nuvec® successfully delivered a plasmid DNA payload in the intestine, which led to significant protein expression and a strong antibody response. CEO Nigel Theobald expressed confidence in Nuvec®’s potential for various medical applications and outlined plans for continued research and development.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
